Protara Therapeutics (TARA) Non Operating Interest Expenses (2014 - 2018)
Protara Therapeutics (TARA) posted quarterly Non Operating Interest Expenses of $411000.0 for Q4 2018, up 3.01% year-over-year from $399000.0 in Q4 2017, and up 3.01% quarter-over-quarter from $399000.0 in Q4 2017.
Protara Therapeutics (TARA) Non Operating Interest Expenses (2014 - 2018) Analysis & Trends
Protara Therapeutics (TARA) has reported Non Operating Interest Expenses for 5 consecutive years, with $411000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non Operating Interest Expenses rose 3.01% year-over-year to $411000.0; the TTM figure through Dec 2018 stood at $411000.0 (up 3.01% YoY), while the FY2018 annual figure was $411000.0, up 3.01% from the prior year.
- Non Operating Interest Expenses advanced to $411000.0 in Q4 2018 per TARA's latest filing, from $399000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $544000.0 in Q4 2016 and bottomed at $27000.0 in Q4 2015.
- Historically, Non Operating Interest Expenses has averaged $371800.0 across 5 years, with a median of $411000.0 in 2018.
- Annual changes were most pronounced in 2015 — Non Operating Interest Expenses plunged 94.35% — and 2016, when it soared 1914.81%.
- Protara Therapeutics' Non Operating Interest Expenses stood at $478000.0 in 2014, then slumped by 94.35% to $27000.0 in 2015, then jumped by 1914.81% to $544000.0 in 2016, then fell by 26.65% to $399000.0 in 2017, then gained by 3.01% to $411000.0 in 2018.
- Business Quant data shows TARA's Non Operating Interest Expenses at $411000.0 in Q4 2018, $399000.0 in Q4 2017, and $544000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 411,000.00 |
| Dec 31, 2017 | 399,000.00 |
| Dec 31, 2016 | 544,000.00 |
| Dec 31, 2015 | 27,000.00 |
| Dec 31, 2014 | 478,000.00 |